| Company* (Country; Symbol) | Company* (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
| 454 Life Sciences* | Perlegen Sciences Inc.* | Agreement to conduct large-scale genetic re-sequencing in hundreds of DNA samples collected by Perlegen from humans with specific responses to a widely prescribed class of drug | Perlegen and 454 each will resequence select portions of the genome within each sample, using 454 Sequencing technology and DNA amplified with Perlegen's sample preparation and amplification technologies (10/2) |
| Accelrys Inc. (ACCL) | Agilent Technologies Inc. (NYSE:A) | Agreement to enable the licensing and integration of their informatics products | The partnership includes the informatics portfolios of both companies (9/25) |
| Affymetrix Inc. (AFFX) | Isogen* (France) | Agreement for nonexclusive access to its microarray technology for the worldwide development and marketing of in vitro diagnostic tests, initially for breast cancer | The deal enables Isogen to incorporate Affymetrix arrays into its diagnostic products (8/28) |
| Agilent Technologies Inc. (NYSE:A) | Strand Life Sciences* (India) | Agreement for Strand to develop Agilent's GeneSpring software | The deal expands on an existing relationship between Stratagene Corp. and Strand (8/20) |
| Alnylam Pharmaceuticals Inc. (ALNY) | GeneDesign Inc.* | Nonexclusive license agreement to provide RNAi research products and services under the Kreutzer-Limmer patent family | The patents cover small interfering RNA is and their use to mediate RNAi in mammalian cells (10/3) |
| Alnylam Pharmaceuticals Inc. (ALNY) | Isis Pharmaceuticals Inc. (ISIS) | Agreement to form the joint venture, Regulus Therapeutics LLC, to focus on microRNA | The companies are exclusively licensing their miRNA intellectual property to Regulus, and Isis will provide a license to several hundred patents covering oligo-nucleotides so that Regulus can develop second-generation antisense compounds (9/7) |
| Anesiva Inc. (ANSV) | Particle Therapeutics Ltd.*(UK) | A specific-use license agreement for Anesiva's drug-delivery technology | It will be incorporated into Particle's needle-free, intradermal delivery system for glucagon, a hormone commonly used to treat hypoglycemia associated with diabetes; Anesiva will receive an up-front payment, as well as milestone payments and royalties (8/30) |
| Applied Biosystems Inc. (NYSE:ABI) | Olink Bioscience* (Sweden) | Exclusive license and collaboration agreement to commercialize Olink's proximity ligation assay technology | Applied Biosystems will co-develop the PLA technology for specific applications in the life science research market that include biomarker validation and characterization of complex biological processes (10/2) |
| Aradigm Corp. (OTC BB:ARDM) | CyDex Inc.* | Two-year collaboration to develop and commercialize combination products con-taining inhaled corticocosteroids, anticholinergics and beta-2 agonists for treating asthma and chronic obstructive pulmonary diseases | Aradigm will cover 60% of collaboration costs, and CyDex 40% (9/6) |
| Aradigm Corp. (OTC BB:ARDM) | Lung Rx Inc.* | Exclusive license, development and commercialization agreement for inhaled treprostinil using Aradigm's AERx Essence technology for the treatment of pulmonary arterial hypertension and other potential therapeutic indications | Aradigm will receive an up-front fee of $440,000 from Lung Rx, followed by an additional $440,000 four months after the signing date; it also includes milestones of up to $9.65M, and Lung Rx will purchase $3.47M of Aradigm's common stock at the average closing price for the 30-day period prior to specified events (9/5) |
| Argenta Discovery Ltd.* (UK) | CellCentric Ltd.* (UK) | Drug discovery collaboration to use Argenta's screening and assay technologies to discover inhibitors for two potential epigenetic-related therapeutic targets | It is a fee-for-service contract arrangement (10/1) |
| Argentis Pharmaceuticals LLC* | LifeCyte Inc.* | Agreement to assist in the design and development of a dedicated cGMP facility that will purify Argentis' collagen products | Initially, bovine native Type I collagen will be purified for use in ARG201, Argentis' treatment for systemic sclerosis (9/24) |
| Array BioPharma Inc. (ARRY) | Celgene Corp. (CELG) | Agreement to discover new compounds for cancer and inflammatory disease | Array received $40M up front and could receive as much as $200M per drug in pre-commercialization milestone payments, and up to $300M in payments related to further success, plus royalties (9/24) |
| Axcan Pharma Inc. (Quebec; AXCA) | Cellerix SL* (Spain) | Exclusive license and development agreement for the North American rights to Cx401, a surgical-procedure product using human adipose tissue | Axcan will make a $10M up-front payment and will pay regulatory milestone payments worth up to $30M, as well as scaled royalties (10/2) |
| BioDelivery Sciences International Inc. (BDSI) | Meda AB (Sweden; SSE: MEDAA) | Licensing agreement for BEMA Fentanyl, a dissolvable opioid disc product | BDSI will receive $30M up front and an additional $30M after BEMA Fentanyl has achieved FDA approval; the firm also is set to receive a double-digit royalty on net sales, as well as $30M in sales milestones (9/5) |
| BioDelivery Sciences International Inc. (BDSI) | QLT USA Inc. (QLTI) | Exercised option agreement for BioDelivery to acquire U.S. rights to the BEMA drug-delivery technology | The acquisition gives BDSI full ownership of the BEMA technology and eliminates any payment of royalties to or the sharing of milestone payments with QLT going forward (9/10) |
| BioLine Rx Ltd.* | Gene Vector Technologies Ltd.* (Israel) | Agreement to develop and commercialize BL-4040, which may protect cells following acute kidney injury | Further details were not disclosed (8/27) |
| BioTrove Inc.* | Charles River Laboratories Inc. (NYSE:CRL) | Agreement for Charles River to use the BioTrove Open-Array system to detect rodent-specific pathogens as part of an effort to evaluate the health of rodent species | Terms were not disclosed (8/28) |
| Cepheid Inc. (CPHD) | Quantovir AB* (Sweden) | Agreement to exclusively license the human papilloma-virus patent portfolio for the quantitative measurement of high-risk HPV types using DNA-based detection | Terms of the deal were not disclosed (9/24) |
| Cisbio International* (France) | Lumiphore Inc.* | Agreement in which Lumiphore's Lumi4 fluorescent lanthanide detection reagent complexes will be incorporated into Cisbio's Time-Resolved Fluorescence Resonance Energy Transfer drug discovery assays | Specific terms were not disclosed (9/5) |
| Clinical Data Inc. (CLDA) | Victorian Clinical Genetics Services*(Australia) | Nonexclusive sublicense agreement to provide genetic testing for familial long QT syndrome of individuals and families in Australia and New Zealand | No other terms of the deal were released (10/1) |
| Crucell NV (the Netherlands; CRXL) | Invitrogen Corp. (IVGN) | Nonexclusive STAR research license | The license covers the production of monoclonal antibodies; terms were not disclosed (9/6) |
| DelSite Biotechnologies Inc. (subsidiary of Carrington Laboratories Inc.; PK:CARN) | Undisclosed biotech company | Technology evaluation rights license deal for transdermal delivery of vaccines using its GelSite polymer, a high-molecular-weight anionic polysaccharide | Financial terms were not disclosed (9/19) |
| Enzon Pharmaceuticals Inc. (ENZN) | Drug Royalty Corp.* | Agreement to sell to Drug Royalty a 25% interest in its royalties from sales of the hepatitis drug Pegintron | Enzon raised $92.5M from the sale; it may receive an additional $15M milestone payment in 2012 if Pegintron meets certain royalty levels (8/20) |
| Fluidigm Corp.* | SAIC-Frederick Inc. (subsidiary of Science Applications International Corp.; NYSE:SAIC) | Agreement for SAIC to use the BioMark system to simplify its genotyping process to test candidate genes against samples from cancer patients | Terms of the deal were not disclosed (9/4) |
| Gene Logic (GLGC) | Ocimum Biosolutions Ltd.* (India) | Agreement for Gene Logic to sell its genomics assets to Ocimum Biosolutions | Ocimum will pay $7M at closing, with the remaining $3M payable pursuant to a promissory note due 18 months after closing (10/15) |
| Genmab A/S (Denmark; CSE:GEN) | Medarex Inc. (MEDX) | Asset-exchange deal that gives Genmab full rights to the antibody HuMax-Inflam (also called MDX-018) | Genmab plans a Phase I/II study with the drug in glioblastoma, with other trials likely in chronic obstructive pulmonary disease (9/13) |
| HistoRx Inc.* | Radiation Therapy Oncology Group (RTSX) | Research collaboration for HistoRx to provide RTOG with AQUA technology and customized immunohisto-chemical assays to research biomarkers associated with brain cancer | HistoRx intends to commercialize assays and reagents developed in the course of the collaboration for clinical use as predictive diagnostics (9/5) |
| Illumigen Biosciences Inc.* | Cubist Pharmaceuticals Inc. (CBST) | Agreement for an option for Cubist to acquire Illumigen | Cubist paid $4.7M for an option to acquire Illumigen; if it chooses to exercise the option, it will pay $9M up front, as well as a potential $75.5M in development and regulatory milestones for IB657 in hepatitis C, $117M in development and regulatory milestones if the drug is pursued in other antiviral indications, $140M in sales milestones and tiered royalties (10/17) |
| Innocoll Technologies Ltd.* (unit of Innocoll Inc.) | TGR Bio-Sciences Pty. Ltd.* (Australia) | Collaboration to evaluate the combination of Innocoll's collagen-based drug delivery technology, CollaRx, with TGR's wound-healing compound, TGR-265 | TGR will fund development of the formulated products (9/12) |
| Integrated Genomics Inc.* | BioBase GmbH* (Germany) | Collaboration to expand and curate Integrated Genomics' ERGO microbial genomic database | BioBase scientists in Bangalore, India, will add manually curated functional gene annotations and pathways to the database (9/25) |
| Invitrogen Corp. (IVGN) | Natural Selection Inc.* | Licensing agreement to make new microRNAs sequences available to researchers | The sequences will be submitted to the on-line database of The Sanger Institute (10/2) |
| Isis Pharmaceuticals Inc. (ISIS) | Altair Therapeutics Inc.* | Licensing agreement for an inhaled asthma product, ISIS 369645, and a collaboration to discover drugs against other respiratory disease targets | Isis, in turn, will own about 18% of the start-up firm and will be eligible for milestones and royalties as ISIS 369645 and any other drugs move through development (10/16) |
| LigoCyte Pharmaceuticals Inc.* | Biogen Idec Inc. (BIIB) | Agreement to develop therapies to treat chronic inflammatory diseases | The firms will develop products that target CD103; LigoCyte is entitled to milestone payments; the companies will share commercialization rights (9/18) |
| MacroChem Corp. (OTC BB: MACM) | Genaera Corp. (GENR) | Exercised option agreement for MacroChem to acquire exclusive, worldwide rights to pexiganan, a small peptide anti-infective, in mild diabetic foot infection | MacroChem will pay Genaera an initial $1M fee through Feb. 1, 2008, and up to $7M in milestones; upon approval, Genaera would be entitled to up to $35M in sales-based milestones and a 10% royalty (10/3) |
| MaxCyte Inc.* | Medinet Co. Ltd. (Japan; PK:MEDB) | Exclusive license to develop and supply MaxCyte's cell loading system to support clinical studies and commercialization of Medinet's cancer immunotherapy service in Japan | MaxCyte will provide the right to use its technology in the closed-system manufacturing of Medinet's immuno-cell therapy service in multiple cell processing centers based on optimized protocols developed under the companies' August 2006 collaboration (8/27) |
| Medarex Inc. (MEDX) | Oxford Genome Sciences Ltd.* (UK) | Agreement for access to Medarex's fully human antibody technology in exchange for undisclosed licensing fees, milestone payments and royalties on commercial sales of any products that may result | OGS will license Medarex's transgenic mouse technology to generate antibody therapeutics against cancer targets that OGS identifies using its OGAP database; OGS will retain full worldwide rights to the new human antibodies generated (9/18) |
| Medicis (NYSE:MRX) | Hyperion Therapeutics Inc.* | Collaboration between Hyperion and Medicis' subsidiary, Ucyclyd Pharma Inc., to conduct research and development of a compound referred to as GT4P for the treatment of urea cycle disorder, hepatic encephalopathies and other indications, and additional indications for Ammonul | Hyperion has paid Ucyclyd $10M for the rights and licenses granted to Hyperion; the deal could entail royalties and mile-stone payments as well (8/28) |
| MedImmune Inc. (LSE:MDI; unit of AstraZeneca plc; UK) | Crucell NV (the Netherlands; CRXL) | Agreement to collaborate in addressing hospital-acquired infections by focusing on the development and commercialization of one of Crucell's panels of bacterial antibodies | MedImmune agreed to provide Crucell up-front, annual and milestone payments potentially exceeding $40M; in addition, Crucell also is entitled to research and development funding and an undisclosed royalty (10/15) |
| MethylGene Inc. (Canada; TSX:MYG) | Pharmion Inc. (PHRM) | Joint research venture to develop small-molecule inhibitors targeting sirtuins | The deal is worth up to $100M and includes royalties on sales in North America ranging from 10.5% to 21% and of 8.5% to 13% for all other licensed territories (8/20) |
| MGI Pharma Inc. (MOGN) | AkaRx Inc.* | Agreement for MGI to gain rights to a midstage thrombo-cytopenia drug, AKR-501 | MGI agreed to pay $45M up front to AkaRx; the deal does not include milestones and royalties; instead, MGI retains an option to acquire AkaRx for $255M any time before Jan. 8, 2010 (8/29) |
| Monogram Biosciences Inc. (MGRM) | Lab21* (UK) | Exclusive partnership under which Lab21 will provide operations and logistics services for Monogram's Trofile assay | Monogram will use Lab21's capabilities to ensure that samples are properly collected and transported to Monogram's laboratory for testing and that results are reported efficiently (10/3) |
| MorphoSys AG (Germany; FSE:MOR) | Genesis Research and Development Corp. Ltd. (New Zealand; NZSE:GEN) | Research agreement in which Genesis will continue to use MorphoSys' HuCAL-based antibodies against the human fibroblast growth factor receptor 5 for target validation and preclinical studies as part of its Zyrogen program | Financial details were not disclosed (10/8) |
| Nanobac Pharmaceuticals Inc. (OTC BB:NNBP) | Calgenex Corp.* | Agreement for treatments used in atherosclerosis, prostatitis and other pathologic calcification diseases | Calgenex has granted Nanobac an option to access its drug delivery technology that includes a novel combination of bisphos-phonate and silicic acid (10/3) |
| Operon Biotechnologies* | DNA2.0 Inc.* | Partnership to combine Operon's oligonucleotide production platform with DNA2.0's gene synthesis process | Operon will co-market DNA2.0's gene synthesis services, while serving as the primary source of oligos for the synthetic genes (8/22) |
| OSI Pharmaceuticals Inc. (OSIP) | AVEO Pharmaceuticals Inc.* | Agreement to advance a cancer drug platform targeting epithelial-to-mesenchymal transition | Terms call for OSI to pay $10M in cash up front, plus to purchase an equity investment valued at about $5M; it also will pay $2.5M per year in research funding for three years, and there are potential milestone and royalty payments down the road (10/2) |
| Plexera Bioscience LLC (subsidiary of Lumera Corp.; LMRA) | MitoSciences Inc.* | Collaboration to develop antibodies and assays for understanding mitochondrial function | The deal outlines a commercial path for an antibody array product enabled with Plexera's ProteomicProcessor and Mito-Sciences' antibodies (9/25) |
| Protox Therapeutics Inc. (Canada; CDNX:PRX) | Medicenna Ventures Inc.* | Agreement to acquire the HUMxin research program from Medicenna | The HUMxin program is focused on developing fully humanized fusion proteins based on the Bcl-2 family of proteins; in exchange, Protox will pay C$209,680 ($197,923), half in cash and half in stock (8/21) |
| PTC Therapeutics Inc.* | Celgene Corp. (CELG) | Agreement for exclusive development rights to orally bioavailable small molecules for two undisclosed oncology targets | PTC is granting Celgene access to Gene Expression Modulation by Small Molecules (GEMS) technology; if Celgene exercises its research option, PTC could receive research funding and earn milestone payments per target; Celgene would receive exclusive worldwide rights and pay PTC royalties on worldwide sales (9/13) |
| RXi Pharmaceuticals* | TriLink Biotechnologies Inc.* | Agreement to exclusively license three RNA interference chemistry technologies for all therapeutic RNAi applications | The agreement includes rights to sublicence a patented RNA linker technology, a patent on RNAi compositions and an un-disclosed chemistry approach that has potential applications in improving RNAi compounds (9/10) |
| ThromboGenics NV (Belgium; BR:THR) | Rhein Minapharm Biogenetics* (subsidiary of Minapharm SAE; Egypt) | Licensing deal for preclinical THR-174 for treating heart attacks | ThromboGenics gets up-front and milestone payments, along with double digit royalties, with Rhein Minapharm paying all future costs (10/4) |
| Tikvah Therapeutics Inc.* | Phase II Discovery Inc.* | Agreement for Tikvah to license worldwide rights to develop and commercialize LY156735 for the treatment of circadian rhythm, sleep disorders, depression and other potential indications | Terms were not disclosed (8/29) |
| Tripos Discovery Research Ltd. (subsidiary of Commonwealth Biotechnologies Inc.; CBTE) | CombinatoRx Inc. (CRXX) | Service agreement for Tripos to provide compu-tational and medicinal chemistry services | Terms of the deal were not disclosed (8/28) |
| Xenomics Inc. (PK:XNOM) | Ipsogen SAS* (France) | Licensing agreement for co-exclusive rights to develop, manufacture and market research and diagnostic products for the stratification and monitoring of patients with acute myeloid leukemia | Terms of the deal were not disclosed (9/17) |
| Notes: | |||
| * Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International. Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
